AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6231942 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Benzoyl peroxide and clindamycin phosphate)
Number of subjects: 0
Study 6231942 — intervention group
Group type: EXPERIMENTAL
Intervention: All three regimens
Number of subjects: 0
Study 30638771 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured personal care (individualized multifactorial treatment)
Number of subjects: 1381
Study 30638771 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1381
Study 30638771 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured personal care
Number of subjects: 1381
Study 27890664 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based hand rubs (ABHR) in addition to usual hand hygiene recommendations
Number of subjects: 236
Study 27890664 — intervention group
Group type: COMPARATOR
Intervention: Usual hand hygiene recommendations (control group)
Number of subjects: 236
Study 27890664 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based hand rubs (ABHR)
Number of subjects: 236
Study 26092822 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise training
Number of subjects: 137
Study 26092822 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 137
Study 26092822 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise training (in patients without previous acute myocardial infarction and diabetes microvascular complications, n=46)
Number of subjects: 137
Study 26092822 — intervention group
Group type: COMPARATOR
Intervention: Control group (in patients without previous acute myocardial infarction and diabetes microvascular complications, n=46)
Number of subjects: 137
Study 24456677 — intervention group
Group type: COMPARATOR
Intervention: Neutral table position
Number of subjects: 19
Study 24456677 — intervention group
Group type: EXPERIMENTAL
Intervention: 5° reverse Trendelenburg position
Number of subjects: 19
Study 24456677 — intervention group
Group type: EXPERIMENTAL
Intervention: 10° reverse Trendelenburg position
Number of subjects: 19
Study 23153661 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of green tea extract 400 mg containing 94% pure EGCG
Number of subjects: 11
Study 19414584 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg twice a day (b.i.d.) for seven doses
Number of subjects: 12
Study 19414584 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 1000 mg twice a day (b.i.d.)
Number of subjects: 12
Study 17440024 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded trials that reported tests for the success of blinding (31 out of 1599 trials, 2%)
Number of subjects: 1599
Study 17440024 — intervention group
Group type: COMPARATOR
Intervention: Trials that did not report tests for the success of blinding (200 trials selected randomly)
Number of subjects: 1599
Study 14711556 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (180 mg/d)
Number of subjects: 25
Study 14711556 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 25
Study 11907847 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate foam (Luxiq) twice a day for four weeks
Number of subjects: 79
Study 11907847 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone valerate foam (Luxiq) once a day for four weeks
Number of subjects: 79
Study 9134274 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril (5 mg daily)
Number of subjects: 30
Study 9134274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 7701055 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (40 mg)
Number of subjects: 18
Study 7701055 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (20 mg)
Number of subjects: 18
Study 7701055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 3323028 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 130
Study 3323028 — intervention group
Group type: COMPARATOR
Intervention: Trichloroacetic acid (TCAA)
Number of subjects: 130
Study 29986448 — intervention group
Group type: COMPARATOR
Intervention: Shooters with BLL ≥ 5 µg/dL
Number of subjects: 118
Study 29986448 — intervention group
Group type: COMPARATOR
Intervention: Shooters
Number of subjects: 118
Study 29986448 — intervention group
Group type: COMPARATOR
Intervention: Shooters with BLL ≥ 10 µg/dL
Number of subjects: 118
Study 28287919 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Project program
Number of subjects: 0
Study 28287919 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 26423850 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill strategy
Number of subjects: 143
Study 26423850 — intervention group
Group type: COMPARATOR
Intervention: Usual medications
Number of subjects: 143
Study 23515338 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led care programme
Number of subjects: 712
Study 23515338 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 712
Study 21931653 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg per day)
Number of subjects: 0
Study 21931653 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (single 5 mg dose)
Number of subjects: 0
Study 19184301 — intervention group
Group type: EXPERIMENTAL
Intervention: Goldmann applanation tonometer (GAT)
Number of subjects: 144
Study 19184301 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontact tonometer (NCT)
Number of subjects: 144
Study 19184301 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable noncontact tonometer (PNCT)
Number of subjects: 144
Study 19184301 — intervention group
Group type: COMPARATOR
Intervention: GAT
Number of subjects: 144
Study 19184301 — intervention group
Group type: COMPARATOR
Intervention: PNCT
Number of subjects: 144
Study 19184301 — intervention group
Group type: COMPARATOR
Intervention: NCT
Number of subjects: 144
Study 17540192 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg/d
Number of subjects: 272
Study 17540192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 15118434 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalexin from day 1 after surgery to 2 days after catheter removal
Number of subjects: 101
Study 15118434 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 101
Study 11495620 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral catheterization
Number of subjects: 289
Study 11495620 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic administration via the catheter
Number of subjects: 289
Study 11495620 — intervention group
Group type: COMPARATOR
Intervention: Subclavian catheterization
Number of subjects: 289
Study 9512207 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram (3.5 mg kg(‐1) bolus followed by 1 mg kg(‐1) h(‐1) infusion)
Number of subjects: 56
Study 9512207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 8893893 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line paclitaxel (200 mg/m2 as a 3-hour infusion) followed by second-line doxorubicin (75 mg/m2 as a bolus injection)
Number of subjects: 330
Study 8893893 — intervention group
Group type: COMPARATOR
Intervention: Second-line doxorubicin (75 mg/m2 as a bolus injection) followed by first-line paclitaxel (200 mg/m2 as a 3-hour infusion)
Number of subjects: 330
Study 2262219 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 0
Study 2262219 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine
Number of subjects: 0
Study 7000105 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid 0.5 g
Number of subjects: 86
Study 7000105 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid 1.0 g
Number of subjects: 86
Study 7000105 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid 0.5 g (without pethidine premedication)
Number of subjects: 86
Study 7000105 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid (without pethidine premedication, thiopentone 4 mg kg‐1)
Number of subjects: 86
Study 7000105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 31280830 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise training (HBET)
Number of subjects: 84
Study 31280830 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 84
Study 28392509 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (25-mg agomelatine)
Number of subjects: 60
Study 28392509 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (25-mg agomelatine)
Number of subjects: 60
Study 28392509 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 60
Study 25575258 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrografin (100 mL administered enterally)
Number of subjects: 75
Study 25575258 — intervention group
Group type: COMPARATOR
Intervention: Flavored distilled water (Control Group)
Number of subjects: 75
Study 25575258 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrografin
Number of subjects: 75
Study 25889222 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA Slim (MTX with prednisone bridging, starting at 30 mg and tapered to 5 mg daily from week 6)
Number of subjects: 90
Study 25889222 — intervention group
Group type: COMPARATOR
Intervention: MTX-TSU (15 mg of MTX weekly)
Number of subjects: 90
Study 25889222 — intervention group
Group type: EXPERIMENTAL
Intervention: COBRA Slim
Number of subjects: 90
Study 25889222 — intervention group
Group type: COMPARATOR
Intervention: MTX-TSU
Number of subjects: 90
Study 25889222 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study 22489871 — intervention group
Group type: EXPERIMENTAL
Intervention: Palpation of bicipital tuberosities
Number of subjects: 25
Study 22489871 — intervention group
Group type: COMPARATOR
Intervention: Real-time ultrasound imaging
Number of subjects: 25
Study 21247553 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive smoke exposure
Number of subjects: 4403
Study 21247553 — intervention group
Group type: EXPERIMENTAL
Intervention: Current active smoking
Number of subjects: 4403
Study 21247553 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing hours per week of passive smoke exposure
Number of subjects: 4403
Study 18451718 — intervention group
Group type: EXPERIMENTAL
Intervention: almotriptan
Number of subjects: 0
Study 18451718 — intervention group
Group type: COMPARATOR
Intervention: indomethacin/caffeine/prochlorperazine
Number of subjects: 0
Study 18451718 — intervention group
Group type: EXPERIMENTAL
Intervention: sumatriptan/naproxen sodium
Number of subjects: 0
Study 18451718 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs (effervescent aspirin)
Number of subjects: 0
Study 16601636 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondrug pain management protocols
Number of subjects: 0
Study 16601636 — intervention group
Group type: EXPERIMENTAL
Intervention: CRU model
Number of subjects: 0
Study 16601636 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondrug interventions
Number of subjects: 0
Study 15189633 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences condition (stereotype threat)
Number of subjects: 0
Study 15189633 — intervention group
Group type: COMPARATOR
Intervention: No differences condition (control)
Number of subjects: 0
Study 10851109 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide (100 mg twice daily for 10 days)
Number of subjects: 104
Study 10851109 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (600 mg three times daily for 10 days)
Number of subjects: 104
Study 9507415 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment (idiopathic cases)
Number of subjects: 9
Study 9507415 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastatic disease at the base of the skull
Number of subjects: 9
Study 9507415 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiari malformation
Number of subjects: 9
Study 9507415 — intervention group
Group type: EXPERIMENTAL
Intervention: Dural arteriovenous fistula of the transverse sinus
Number of subjects: 9
Study 7810816 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 40 mg/kg as a single oral dose
Number of subjects: 40
Study 2467132 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg single oral dose
Number of subjects: 16
Study 29198820 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral amoxicillin plus resveratrol (AX + RV)
Number of subjects: 647
Study 29198820 — intervention group
Group type: COMPARATOR
Intervention: Oral amoxicillin plus placebo (AX + placebo)
Number of subjects: 647
Study 28743659 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology intervention (four weekly sessions, caregiver-delivered, 30-minute protocol)
Number of subjects: 256
Study 28743659 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 256
Study 28743659 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology intervention
Number of subjects: 256
Study 26367865 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibudilast 40 mg twice daily for 8 weeks
Number of subjects: 34
Study 26367865 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 23187429 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin traction
Number of subjects: 81
Study 23187429 — intervention group
Group type: COMPARATOR
Intervention: Bed rest (no traction)
Number of subjects: 81
Study 21971895 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 150
Study 21971895 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current
Number of subjects: 150
Study 21971895 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study 18420431 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine (A200)
Number of subjects: 50
Study 18420431 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine (B200)
Number of subjects: 50
Study 16509026 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 1000
Study 16509026 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 1000
Study 16509026 — intervention group
Group type: COMPARATOR
Intervention: Nesiritide and dobutamine
Number of subjects: 1000
Study 12699517 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg(‐1) and lidocaine 1.5 mg kg(‐1)
Number of subjects: 125
Study 12699517 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium 0.6 mg kg(‐1)
Number of subjects: 125
Study 12699517 — intervention group
Group type: COMPARATOR
Intervention: Succinylcholine
Number of subjects: 125
Study 12699517 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium-lidocaine
Number of subjects: 125
Study 15529572 — intervention group
Group type: EXPERIMENTAL
Intervention: Climen (estrogens and cyproteronate)
Number of subjects: 121
Study 15529572 — intervention group
Group type: EXPERIMENTAL
Intervention: Progynova (estrogens)
Number of subjects: 121
Study 15529572 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pl)
Number of subjects: 121
Study 9558630 — intervention group
Group type: EXPERIMENTAL
Intervention: Otoacoustic emission testing in miners exposed to noise
Number of subjects: 74
Study 9558630 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonexposed to noise)
Number of subjects: 74
Study 11271285 — intervention group
Group type: EXPERIMENTAL
Intervention: Histidine‐Tryptophane‐Ketoglutarate (HTK) solution
Number of subjects: 0
Study 11271285 — intervention group
Group type: EXPERIMENTAL
Intervention: University of Wisconsin (UW) solution
Number of subjects: 0
Study 11271285 — intervention group
Group type: COMPARATOR
Intervention: Euro‐Collins (EC) solution
Number of subjects: 0
Study 2853765 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (20‐80 mg/day)
Number of subjects: 26
Study 2853765 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50‐200 mg/day)
Number of subjects: 26
Study 2853765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 31081651 — intervention group
Group type: EXPERIMENTAL
Intervention: WebMOVE (web-based weight-management intervention)
Number of subjects: 277
Study 31081651 — intervention group
Group type: COMPARATOR
Intervention: MOVE-SMI (in-person weight-management intervention)
Number of subjects: 277
Study 31081651 — intervention group
Group type: EXPERIMENTAL
Intervention: Both WebMOVE and MOVE-SMI
Number of subjects: 277
Study 27227791 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cryotherapy (WBC) session (30 seconds at -60° C, 120 seconds at -135° C)
Number of subjects: 14
Study 27227791 — intervention group
Group type: COMPARATOR
Intervention: Control (Con) - remained seated indoors at ∼25° C
Number of subjects: 14
Study 25695081 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase I procedures (soft tissue surgery)
Number of subjects: 46
Study 25695081 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase II procedures (orthognathic surgery)
Number of subjects: 46
Study 25695081 — intervention group
Group type: COMPARATOR
Intervention: No surgery patients (control group)
Number of subjects: 46
Study 23747044 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel treatment with high residual platelet reactivity (RPR) diagnosed on P2Y₁₂ reaction units >230
Number of subjects: 833
Study 23747044 — intervention group
Group type: COMPARATOR
Intervention: Good responders to clopidogrel treatment
Number of subjects: 833
Study 21968457 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month psychotherapy intervention
Number of subjects: 52
Study 21968457 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 52
Study 18682875 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch surgery
Number of subjects: 655
Study 18682875 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial sling
Number of subjects: 655
Study 18682875 — intervention group
Group type: COMPARATOR
Intervention: Control group (unsuccessful surgery)
Number of subjects: 655
Study 17144551 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle exercise in the free load regimen
Number of subjects: 0
Study 12759268 — intervention group
Group type: EXPERIMENTAL
Intervention: SP/AP area curve ratio
Number of subjects: 8
Study 12759268 — intervention group
Group type: EXPERIMENTAL
Intervention: SP/AP amplitude ratio
Number of subjects: 8
Study 12759268 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal SP/AP ratios)
Number of subjects: 8
Study 11107088 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous cuff at the venous anastomosis
Number of subjects: 120
Study 11107088 — intervention group
Group type: COMPARATOR
Intervention: No venous cuff
Number of subjects: 120
Study 11107088 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous cuff
Number of subjects: 120
Study 11107088 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial anastomosing vein diameter < 4 mm
Number of subjects: 120
Study 11107088 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial anastomosing vein diameter ≥ 4 mm
Number of subjects: 120
Study 11107088 — intervention group
Group type: EXPERIMENTAL
Intervention: Local conditions (edema, skin atrophy, obesity)
Number of subjects: 120
Study 8937802 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro Plus Spirometer (MP)
Number of subjects: 0
Study 8937802 — intervention group
Group type: COMPARATOR
Intervention: Vitalograph bellow spirometer (V)
Number of subjects: 0
Study 8937802 — intervention group
Group type: COMPARATOR
Intervention: Wright PEF meter (W)
Number of subjects: 0
Study 1556953 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise without calorie restriction
Number of subjects: 3
Study 1556953 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction without exercise
Number of subjects: 3
Study 1556953 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 3
Study 3883167 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental mastectomy plus radiation
Number of subjects: 1843
Study 3883167 — intervention group
Group type: COMPARATOR
Intervention: Segmental mastectomy alone
Number of subjects: 1843
Study 3883167 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental mastectomy with radiation
Number of subjects: 1843
Study 3883167 — intervention group
Group type: COMPARATOR
Intervention: Segmental mastectomy without radiation
Number of subjects: 1843
Study 3883167 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental mastectomy with radiation among patients with positive nodes
Number of subjects: 1843
Study 3883167 — intervention group
Group type: COMPARATOR
Intervention: Segmental mastectomy without radiation among patients with positive nodes
Number of subjects: 1843
Study 30633139 — intervention group
Group type: EXPERIMENTAL
Intervention: Riboflavin 400 mg
Number of subjects: 66
Study 30633139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 29257143 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential electrical stimulation plus pelvic floor muscle exercises
Number of subjects: 90
Study 29257143 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle exercises plus sham stimulation
Number of subjects: 90
Study 26461929 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial cervical length (CL) ≥39 mm
Number of subjects: 786
Study 26461929 — intervention group
Group type: COMPARATOR
Intervention: Initial cervical length (CL) <39 mm
Number of subjects: 786
Study 26461929 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial cervical length (CL) <25 mm or SPTB before follow-up CL
Number of subjects: 786
Study 26461929 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial cervical length (CL) ≥25 mm
Number of subjects: 786
Study 26461929 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operator characteristics curve
Number of subjects: 786
Study 26461929 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial cervical length cutoffs
Number of subjects: 786
Study 24905030 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg robatumumab followed by 10 mg/kg biweekly in P2
Number of subjects: 41
Study 24905030 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg robatumumab in P2
Number of subjects: 41
Study 24905030 — intervention group
Group type: COMPARATOR
Intervention: 0.3 mg/kg robatumumab
Number of subjects: 41
Study 21937177 — intervention group
Group type: EXPERIMENTAL
Intervention: CT/US fusion imaging during pRFA (group 1)
Number of subjects: 37